TF Capital

TF Capital is a venture capital firm based in Shanghai, China, founded in November 2013. The firm specializes in early-stage and growth capital investments primarily in the life sciences sector. Its focus areas include biotechnology, therapeutics, pharmaceuticals, drug delivery, medical devices, and medical services. TF Capital aims to support preclinical and early clinical-stage companies, contributing to innovation and development in the life sciences industry.

Wei Cheng

Managing Director

H.J. Jiang

Founder and CEO

Allan Liu

Managing Director

Yi Liu

Director

Dr. Zhang Yibo

Partner

Xinzhong Wang Ph.D

Venture Partner

53 past transactions

Avenzo

Series A in 2024
Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Avenzo

Series A in 2024
Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Sanegene Bio

Series A in 2023
Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Neowise

Series A in 2023
XinjingZhiyuan is an immune cell therapy company focusing on solid tumors.

Allorion Therapeutics

Series B in 2023
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

AskGene Pharma

Series A in 2022
AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.

UniXell Biotechnology

Seed Round in 2022
UniXell Biotechnology is a developer of cell therapies utilizing human pluripotent stem cell technology. The company focuses on addressing unmet medical needs in neurodegenerative diseases, rare diseases, and tumors. UniXell has established multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology, and high-precision gene editing. These innovations enable the development of effective treatment solutions aimed at improving the lives of patients suffering from complex medical conditions. The company's proprietary intellectual property encompasses various aspects of stem cell preparation, cultivation, differentiation, and gene editing, positioning it as a leader in the advancement of cellular therapies.

UniXell

Seed Round in 2022
UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

Chemsemi

Series A in 2022
ChemSemi develops 5G chips and semiconductor technologies.

Hesguard

Seed Round in 2021
Hesguard is a medical device developer and producer of high-end implantable medical devices related to ophthalmic diseases.

Allorion Therapeutics

Series A in 2021
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.

Positive Sequence Biology

Series A in 2021
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Structure Therapeutics

Series B in 2021
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Cellular Biomedicine Group

Series A in 2021
Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer and stem cell therapies for degenerative diseases, particularly in Greater China. The company utilizes proprietary cell-based technologies to create treatments, including various forms of CAR-T therapies targeting different cancer types, such as CD20 for anti-tumor activities, CD22 for B cell malignancies, and therapies aimed at refractory multiple myeloma. Additionally, the company develops NKG2D CAR therapies and treatments for hepatocellular carcinoma, alongside knee osteoarthritis therapies currently undergoing clinical trials. Beyond its therapeutic development, Cellular Biomedicine Group is involved in biopharmaceutical activities encompassing research and development, technical support, and the manufacturing of pharmaceutical products and medical devices. It also operates under a collaboration agreement with Novartis Pharma AG to manufacture and supply the CAR-T cell therapy Kymriah in China. Established in 2001, the company integrates over thirty years of research and clinical experience in cellular medicine, drawing on expertise from collaborations among scientists and medical professionals across the United States, England, and China.

Coordination Pharmaceuticals

Venture Round in 2021
Coordination Pharmaceuticals is a drug development company that aims to address unmet medical needs and improve patient care. The NCP platform was pioneered by the lab of Professor Wenbin Lin at the University of Chicago. As a versatile technology platform, NCP components can be purposefully chosen to synergize with and enhance currently existing therapies. CPI products are especially potent in combination with checkpoint blockade inhibitors by increasing T cell infiltration into lowly immunogenic solid tumors.

CytoLynx Therapeutics

Funding Round in 2021
CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.

Etern

Series B in 2021
Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.

Abogen Biosciences

Series B in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Newsoara

Venture Round in 2021
Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Regor Therapeutics

Series B in 2021
Regor Therapeutics is a clinical-stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.

QL Biopharma

Venture Round in 2021
QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases.

SciNeuro

Series A in 2020
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.

Angitia Biopharmaceuticals

Series A in 2020
Angitia Biopharmaceuticals is a global biotechnology company dedicated to discovering and developing innovative therapeutics for serious musculoskeletal diseases. The company focuses on researching and creating breakthrough therapies aimed at treating conditions affecting bones, muscles, and joints. By prioritizing the development of novel drugs, Angitia Biopharmaceuticals aims to improve patient outcomes and facilitate recovery from severe musculoskeletal ailments.

Hanyu Medical

Series D in 2020
Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices. Specializing in minimally invasive treatments for mitral valve regurgitation, the company’s flagship product is the Valve Clamp, an interventional device designed to assist in the closure of heart valves during surgical procedures. By focusing on innovative solutions for heart valve diseases, Hanyu Medical aims to enhance surgical outcomes and patient recovery through its advanced medical technologies.

Ranok Therapeutics

Seed Round in 2020
Ranok Therapeutics is a biotechnology company focused on developing targeted protein degradation technology to discover and create new therapeutics. This innovative approach engages various biological processes and demonstrates superiority over existing targeted protein degradation methods. The company's pipeline includes both well-established and novel drug targets associated with cancer and other diseases that present significant unmet medical needs. Ranok is committed to advancing the next generation of cancer therapies that prioritize safety and effectiveness for patients facing serious health challenges.

Oceanus Plus

Series A in 2020
Oceanus Plus focuses on the development of clinical research products and has independent intellectual property rights.

EOC Pharma Group

Series C in 2019
EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China. They have adopted a licensing model in order to build EOC’s innovative pipeline by plugging their partner’s molecule into EOC’s “core engine” of local manufacturing, clinical development, regulatory filing, and commercialization. The company has a pipeline of seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China.,EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles. EOC will leverage forward-looking licensing which will provide product opportunities to their integrated platform, generating a highly strategic portfolio. Ultimately, this will position EOC at the top of oncology innovation in China.

Tisenc

Series C in 2019
Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology (CLIA) systems, including advanced point-of-care testing (POCT) systems and molecular diagnostic solutions. Tisenc operates from a facility covering over 16,000 square meters, which houses research and development laboratories, a GMP-certified factory, and an instrument manufacturing facility. The company holds full intellectual property rights for its products and technologies, allowing for complete independence in research, development, and production. Tisenc's innovative technologies support medical practitioners by providing reliable diagnostic reagents and automatic chemiluminescent analyzers, contributing significantly to the field of medical diagnostics.

GeneQuantum Healthcare

Series B in 2019
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company specializing in the research and development of innovative biotherapeutics, particularly in the field of anti-tumor therapies. Founded in August 2013 in Suzhou Industrial Park, the company has established a world-class bio-conjugation technology platform that utilizes a ligase-dependent conjugation method. This advanced technology significantly enhances the therapeutic window for developing a series of next-generation Antibody-Drug-Conjugates (ADCs). GeneQuantum is actively working on advancing its ADC candidates towards Investigational New Drug (IND) applications in both the United States and China, while also focusing on expanding its product pipeline to address unmet medical needs in cancer treatment.

Abbisko Therapeutics

Series B in 2019
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

Zion Pharma

Series A in 2019
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.

Antengene

Series B in 2019
Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

BioNova Pharma

Series A in 2018
BioNova Pharma biopharmaceutical company that develops and commercializes innovative medicines for cancer and other life-threatening diseases. The company is expanding company with a strong pipeline based on in-house R&D initiatives, partnerships with, and purchases from partners with cutting-edge technology. The goal of BioNova is to close the gap between the high unmet medical needs and the dearth of innovative medicines by developing an innovative R&D platform with a substantial pipeline to address multiple disease areas.

GenFleet Therapeutics

Series A in 2018
GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.

Xgene Pharmaceutical

Series B in 2018
Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.

ECCOGENE

Series A in 2018
Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolism and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, aiming to create immunological pharmaceuticals at the molecular level to address complex chronic conditions such as obesity and diabetes. Through its innovative approach, Eccogene is building a pipeline of metabolic drugs designed to enhance patient outcomes and improve health conditions related to these chronic diseases.

Alpha Biopharma

Series A in 2018
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.

Tisenc

Series A in 2018
Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology (CLIA) systems, including advanced point-of-care testing (POCT) systems and molecular diagnostic solutions. Tisenc operates from a facility covering over 16,000 square meters, which houses research and development laboratories, a GMP-certified factory, and an instrument manufacturing facility. The company holds full intellectual property rights for its products and technologies, allowing for complete independence in research, development, and production. Tisenc's innovative technologies support medical practitioners by providing reliable diagnostic reagents and automatic chemiluminescent analyzers, contributing significantly to the field of medical diagnostics.

XPECT Vision

Series B in 2018
Xpect Vision, founded in 2015, is a high-tech company specializing in the development of innovative medical imaging technologies. The company focuses on photon-counting X-ray imaging and is advancing the field with the creation of high-speed, high-definition imaging chips. Xpect Vision manufactures imaging chips that utilize digital X-ray imaging technology and CMOS X-ray detection methods, which are designed to enhance medical detection services. These products aim to improve the accuracy of cancer diagnoses, enabling physicians to deliver more efficient and effective healthcare solutions. Through its commitment to disruptive technology development, Xpect Vision is positioning itself as a leader in the future of imaging technology.

Xgene Pharmaceutical

Series A in 2017
Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.

Antengene

Series A in 2017
Antengene Corporation is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2016. The company specializes in the development of innovative oncology therapies, focusing on treatments for various types of cancers, including hematologic malignancies and solid tumors. Antengene's product portfolio includes ATG-010 (selinexor), which targets XPO1 for treating multiple myeloma and DLBCL, and ATG-008 (onatasertib), an mTOR kinase inhibitor for advanced solid tumors. The company’s pipeline also features several compounds in various stages of development, such as ATG-016, ATG-527, ATG-019, and ATG-017, each targeting specific cancer pathways. In addition to its clinical programs, Antengene is involved in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics, aiming to address unmet medical needs in the oncology field across Asia.

TongliBio

Private Equity Round in 2017
TongliBio is a biotechnology company focused on developing innovative medical products to address unmet medical needs, particularly in the realm of tropical diseases. The company engages in the discovery of new drugs and translational medicine, conducting pioneering preclinical and clinical research on anti-infectious agents. Additionally, TongliBio utilizes proprietary chemoenzymatic process technology to promote green pharmaceutical manufacturing, striving to deliver affordable and high-quality medical solutions for infectious diseases.

GeneQuantum Healthcare

Series A in 2017
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company specializing in the research and development of innovative biotherapeutics, particularly in the field of anti-tumor therapies. Founded in August 2013 in Suzhou Industrial Park, the company has established a world-class bio-conjugation technology platform that utilizes a ligase-dependent conjugation method. This advanced technology significantly enhances the therapeutic window for developing a series of next-generation Antibody-Drug-Conjugates (ADCs). GeneQuantum is actively working on advancing its ADC candidates towards Investigational New Drug (IND) applications in both the United States and China, while also focusing on expanding its product pipeline to address unmet medical needs in cancer treatment.

Abbisko Therapeutics

Series A in 2017
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

Asieris Pharmaceuticals

Series A in 2016
Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010, headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris is committed to advancing therapeutic solutions that integrate both diagnosis and treatment, catering to the needs of patients in China and globally. Through its innovative approach, the company seeks to contribute significantly to the fields of oncology and infectious disease management.

Hua Medicine

Series C in 2016
Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Zai Lab

Series B in 2016
Zai Lab Limited is a biopharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2013, the company has established a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Ripretinib for KIT and PDGFRa-driven cancers, and Margetuximab for breast and gastric cancers. Zai Lab also develops antibiotics such as Omadacycline and Durlobactam for bacterial infections. The company seeks to address unmet medical needs in China and globally by leveraging partnerships with leading biopharmaceutical firms and utilizing its in-house manufacturing capabilities. Zai Lab aims to establish itself as a fully integrated biopharmaceutical entity, enhancing its drug development efforts through collaborations with academic institutions and expanding its commercial reach in the Chinese market.

Wecare Probiotics

Venture Round in 2016
Wecare Probiotics is a national high-tech enterprise specializing in the R & D, production, and application of probiotic strains.

Ark Biosciences

Series A in 2015
Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development of innovative therapeutics to address unmet medical need, especially in the area of respiratory viral infection and viral hepatitis, for global and China market. We strive to build a science-driven biopharmaceutical company that aims to be a leader in antiviral drug discovery and development. To achieve so, we aspire for the excellence of science and be innovative. We operate with a razor-sharp focus and aggressiveness with a timely and cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners.

Hua Medicine

Series B in 2015
Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

CANbridge Pharmaceuticals

Series A in 2014
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

Zai Lab

Series A in 2014
Zai Lab Limited is a biopharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2013, the company has established a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Ripretinib for KIT and PDGFRa-driven cancers, and Margetuximab for breast and gastric cancers. Zai Lab also develops antibiotics such as Omadacycline and Durlobactam for bacterial infections. The company seeks to address unmet medical needs in China and globally by leveraging partnerships with leading biopharmaceutical firms and utilizing its in-house manufacturing capabilities. Zai Lab aims to establish itself as a fully integrated biopharmaceutical entity, enhancing its drug development efforts through collaborations with academic institutions and expanding its commercial reach in the Chinese market.

Shanghai Sanyou Medical

Series A in 2014
Shanghai Sanyou Medical Co., Ltd specializes in the research and development, manufacturing, and sales of innovative orthopedic implants and medical devices. The company is located in the Medical Apparatus Garden of Zhangjiang Hi-Tech Park in Shanghai. Its product range includes type III implantation equipment for orthopedics, type III intracranial hematoma puncture removal equipment, as well as various types of surgical instruments and nursing materials. Since its restructuring in September 2010, the company has aimed to establish a sustainable and valuable presence in the medical device industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.